Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Mount Sinai, New York

King Chulalongkorn Memorial Hospital, Bangkok

Seoul National University Bundang Hospital, Seongnam-si

University of Rochester Medical Center, Rochester

University of Pittsburgh Cancer Institute, Pittsburgh

Lombardi Cancer Center, Georgetown University, Washington D.C.

Johns Hopkins, Baltimore

Duke Cancer Institute, Durham

Medical University of South Carolina, Charleston

Gabrail Cancer Center, Canton

Maharaj Nakorn Chiang Mai Hospital, Chiang Mai

Froedtert Hospital And Medical College, Milwaukee

Washington University School of Medicine, St Louis

MD Anderson Cancer Center, Houston

UT Health Cancer Center, San Antonio

Huntsman Cancer Institute, Salt Lake City

Mayo Clinic of Arizona, Phoenix

University of Arizona, Tucson

USC/Norris Comprehensive Cancer Center, Los Angeles

Prince of Songkla University, Hat Yai

UCLA - David Geffen School of Medicine, Santa Monica

The Oncology Institute of Hope and Innovation, Whittier

City of Hope, Duarte

Scripps, La Jolla

University of California Irvine Division of Hematology-Oncology, Department of Medicine UC Irvine Health, Orange

UC Davis, Sacramento

Virginia Mason, Seattle

Seattle Cancer Care Alliance, Seattle

Yale Cancer Center, New Haven

Beth Israel Deaconess Medical Center, Boston

Samsung Medical Center, Seoul

Korea University Guro Hospital, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Asan Medical Center, Seoul